OrsoBio

OrsoBio is pleased to announce an oversubscribed $67M Series B financing to support advancement of our mitochondrial protonophore portfolio for the treatment of obesity and associated disorders. Special thanks to our new investors, Ascenta Capital and Woodline Partners LP , and to our existing investors, Samsara BioCapital, Longitude Capital, Enavate Sciences, Eli Lilly and Company, and NuevaBio, for their continued support. Read the announcement here: https://bit.ly/3Xye1HY

OrsoBio is at #ADA2024 and today will present the first of 3 posters describing progress with TLC-6740, our liver-targeted mitochondrial protonophore in development for obesity and associated disorders. Stop by late-breaking poster #1866-LB to learn about our Ph 1 study which demonstrated excellent safety, target engagement and metabolic benefit of TLC-6740 in healthy subjects!

Thanks to Brian K. Buntz and Drug Discovery & Development for highlighting our programs and complementarity to #glp1 receptor agonists. https://lnkd.in/gBBEVvrd

At AASLD’s #tlm23 this weekend, OrsoBio collaborators Yasmine Liu, Ph.D., Prof. Johan Auwerx, and Takanori Takebe presented beautiful data showing the benefits of ACMSD inhibition with TLC-065 to increase hepatic NAD+, reduce inflammation and fibrosis, and enhance mitochondrial function in mouse hepatocytes, a diet-induced thermoneutrality mouse model of NASH, and in iPSC-derived human liver organoids from NASH patients. These data support the potential of ACMSD inhibition to improve liver disease due to #NASH and other etiologies. Read more here: https://lnkd.in/gq7-zvcr

OrsoBio roars with $60m to treat metabolic disorders Company targets metabolism with therapies to restore energy stability and prevent organ dysfunction. #longevity #investment #obesity

Today OrsoBio announced a $60M Series A financing to support advancement of our metabolic portfolio for the treatment of obesity and related disorders. We're thrilled to welcome our new investors, Longitude Capital, Enavate Sciences, and Eli Lilly and Company, and for the continued support from our existing investors, Samsara BioCapital and NuevaBio, as we embark on the next stage of our journey. Read the announcement here: https://lnkd.in/gEBDii36

We're excited to present Phase 1 data for our liver-targeted LXR inverse agonist, TLC-2716, at?#AHA23?this week. The data demonstrate dose-dependent improvements in atherogenic lipids (e.g., TGs, LDL-C, LDL particles, apoB) and support Phase 2 development in severe hypertriglyceridemia and #NASH. Read more here:?https://bwnews.pr/3sweuii